Pure Global AI
NCT06327516Recruiting

Lysophosphatidylglycerol in Asthma Pathogenesis

Peking University Third HospitalClinicalTrials.gov
Verified
Study focus
Disease/Condition
Asthma
Study type
Observational
Sponsor & location
Primary sponsor
Peking University Third Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2015
End date
Jun 30, 2025
Enrollment
250 participants
Primary outcome

lipidomics

Summary

The study aims to investigate the relationship between the small molecule metabolite
 lysophosphatidylglycerol and asthma clinical features and explore its involvement in asthma
 pathogenesis.

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06327516
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06327516 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University Third Hospital and is currently Recruiting. The study focuses on Asthma. Target enrollment is 250 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.